APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drug Carcinogenicity Testing

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Drug Carcinogenicity Testing Market Outlook and Growth Opportunities 2026

4 March 2026194 pages

Choose your research edition.

Industry ResearchDrug Carcinogenicity Testing Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Drug Carcinogenicity Testing Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Drug Carcinogenicity Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drug Carcinogenicity Testing Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Drug Carcinogenicity Testing Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Drug Carcinogenicity Testing market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Drug Carcinogenicity Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drug Carcinogenicity Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drug Carcinogenicity Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Drug Carcinogenicity Testing market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Drug Carcinogenicity Testing market include Inotiv, Charles River Laboratories, Creative Biolabs, Vivotecnia, Aurigene Pharmaceutical Services, Lhasa Limited, Wako Pure Chemical Industries, Ichor Life Sciences and Frontage Labs, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Drug Carcinogenicity Testing market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drug Carcinogenicity Testing and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drug Carcinogenicity Testing revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Drug Carcinogenicity Testing market.

Drug Carcinogenicity Testing Segment by Company

Inotiv

Charles River Laboratories

Creative Biolabs

Vivotecnia

Aurigene Pharmaceutical Services

Lhasa Limited

Wako Pure Chemical Industries

Ichor Life Sciences

Frontage Labs

WuXi AppTec

Nanjing Enhancer

Drug Carcinogenicity Testing Segment by Type

Transgenic Mouse Assay

Mouse Bioassay

Drug Carcinogenicity Testing Segment by Application

Medicine

Pharmaceutical

Drug Carcinogenicity Testing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Drug Carcinogenicity Testing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Drug Carcinogenicity Testing key companies, revenue, market share, and recent developments.

3. To split the Drug Carcinogenicity Testing breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Drug Carcinogenicity Testing market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drug Carcinogenicity Testing significant trends, drivers, influence factors in global and regions.

6. To analyze Drug Carcinogenicity Testing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drug Carcinogenicity Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drug Carcinogenicity Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drug Carcinogenicity Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drug Carcinogenicity Testing industry.

Chapter 3: Detailed analysis of Drug Carcinogenicity Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Drug Carcinogenicity Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Drug Carcinogenicity Testing in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drug Carcinogenicity Testing Industry Trends Table 2. Drug Carcinogenicity Testing Industry Drivers Table 3. Drug Carcinogenicity Testing Industry Opportunities and Challenges Table 4. Drug Carcinogenicity Testing Industry Restraints Table 5. Global Drug Carcinogenicity Testing Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drug Carcinogenicity Testing Revenue Share by Company (2021-2026) Table 7. Global Drug Carcinogenicity Testing Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Drug Carcinogenicity Testing Key Company Manufacturing Base & Headquarters Table 9. Global Drug Carcinogenicity Testing Company, Product Type & Application Table 10. Global Drug Carcinogenicity Testing Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Drug Carcinogenicity Testing by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Transgenic Mouse Assay Table 15. Significant Companies of Mouse Bioassay Table 16. Global Drug Carcinogenicity Testing Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Drug Carcinogenicity Testing Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Drug Carcinogenicity Testing Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Drug Carcinogenicity Testing Sales Value Share by Type (2021-2026) Table 20. Global Drug Carcinogenicity Testing Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Medicine Table 22. Significant Companies of Pharmaceutical Table 23. Global Drug Carcinogenicity Testing Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Drug Carcinogenicity Testing Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Drug Carcinogenicity Testing Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Drug Carcinogenicity Testing Sales Value Share by Application (2021-2026) Table 27. Global Drug Carcinogenicity Testing Sales Value Share by Application (2027-2032) Table 28. Global Drug Carcinogenicity Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Drug Carcinogenicity Testing Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Drug Carcinogenicity Testing Sales Value Share by Region (2021-2026) Table 31. Global Drug Carcinogenicity Testing Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Drug Carcinogenicity Testing Sales Value Share by Region (2027-2032) Table 33. Global Drug Carcinogenicity Testing Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Drug Carcinogenicity Testing Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Drug Carcinogenicity Testing Sales Value Market Share by Country (2021-2026) Table 36. Global Drug Carcinogenicity Testing Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Drug Carcinogenicity Testing Sales Value Market Share by Country (2027-2032) Table 38. Inotiv Company Information Table 39. Inotiv Business Overview Table 40. Inotiv Drug Carcinogenicity Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Inotiv Drug Carcinogenicity Testing Product Portfolio Table 42. Inotiv Recent Development Table 43. Charles River Laboratories Company Information Table 44. Charles River Laboratories Business Overview Table 45. Charles River Laboratories Drug Carcinogenicity Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Charles River Laboratories Drug Carcinogenicity Testing Product Portfolio Table 47. Charles River Laboratories Recent Development Table 48. Creative Biolabs Company Information Table 49. Creative Biolabs Business Overview Table 50. Creative Biolabs Drug Carcinogenicity Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Creative Biolabs Drug Carcinogenicity Testing Product Portfolio Table 52. Creative Biolabs Recent Development Table 53. Vivotecnia Company Information Table 54. Vivotecnia Business Overview Table 55. Vivotecnia Drug Carcinogenicity Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Vivotecnia Drug Carcinogenicity Testing Product Portfolio Table 57. Vivotecnia Recent Development Table 58. Aurigene Pharmaceutical Services Company Information Table 59. Aurigene Pharmaceutical Services Business Overview Table 60. Aurigene Pharmaceutical Services Drug Carcinogenicity Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Aurigene Pharmaceutical Services Drug Carcinogenicity Testing Product Portfolio Table 62. Aurigene Pharmaceutical Services Recent Development Table 63. Lhasa Limited Company Information Table 64. Lhasa Limited Business Overview Table 65. Lhasa Limited Drug Carcinogenicity Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Lhasa Limited Drug Carcinogenicity Testing Product Portfolio Table 67. Lhasa Limited Recent Development Table 68. Wako Pure Chemical Industries Company Information Table 69. Wako Pure Chemical Industries Business Overview Table 70. Wako Pure Chemical Industries Drug Carcinogenicity Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Wako Pure Chemical Industries Drug Carcinogenicity Testing Product Portfolio Table 72. Wako Pure Chemical Industries Recent Development Table 73. Ichor Life Sciences Company Information Table 74. Ichor Life Sciences Business Overview Table 75. Ichor Life Sciences Drug Carcinogenicity Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Ichor Life Sciences Drug Carcinogenicity Testing Product Portfolio Table 77. Ichor Life Sciences Recent Development Table 78. Frontage Labs Company Information Table 79. Frontage Labs Business Overview Table 80. Frontage Labs Drug Carcinogenicity Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Frontage Labs Drug Carcinogenicity Testing Product Portfolio Table 82. Frontage Labs Recent Development Table 83. WuXi AppTec Company Information Table 84. WuXi AppTec Business Overview Table 85. WuXi AppTec Drug Carcinogenicity Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. WuXi AppTec Drug Carcinogenicity Testing Product Portfolio Table 87. WuXi AppTec Recent Development Table 88. Nanjing Enhancer Company Information Table 89. Nanjing Enhancer Business Overview Table 90. Nanjing Enhancer Drug Carcinogenicity Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Nanjing Enhancer Drug Carcinogenicity Testing Product Portfolio Table 92. Nanjing Enhancer Recent Development Table 93. Research Programs/Design for This Report Table 94. Authors List of This Report Table 95. Secondary Sources Table 96. Primary Sources List of Figures Figure 1. Drug Carcinogenicity Testing Product Image Figure 2. Global Drug Carcinogenicity Testing Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drug Carcinogenicity Testing Market Size (2021-2032) & (US$ Million) Figure 4. Global Drug Carcinogenicity Testing Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Transgenic Mouse Assay Image Figure 8. Mouse Bioassay Image Figure 9. Global Drug Carcinogenicity Testing Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Drug Carcinogenicity Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Drug Carcinogenicity Testing Sales Value Share by Type (2021-2032) Figure 12. Medicine Image Figure 13. Pharmaceutical Image Figure 14. Global Drug Carcinogenicity Testing Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Drug Carcinogenicity Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Drug Carcinogenicity Testing Sales Value Share by Application (2021-2032) Figure 17. Global Drug Carcinogenicity Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Drug Carcinogenicity Testing Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Drug Carcinogenicity Testing Sales Value (2021-2032) & (US$ Million) Figure 20. North America Drug Carcinogenicity Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Drug Carcinogenicity Testing Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Drug Carcinogenicity Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Drug Carcinogenicity Testing Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Drug Carcinogenicity Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Drug Carcinogenicity Testing Sales Value (2021-2032) & (US$ Million) Figure 26. South America Drug Carcinogenicity Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Drug Carcinogenicity Testing Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Drug Carcinogenicity Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Transgenic Mouse Assay
  • Mouse Bioassay
Applications
  • Medicine
  • Pharmaceutical
Companies covered
  • Inotiv
  • Charles River Laboratories
  • Creative Biolabs
  • Vivotecnia
  • Aurigene Pharmaceutical Services
  • Lhasa Limited
  • Wako Pure Chemical Industries
  • Ichor Life Sciences
  • Frontage Labs
  • WuXi AppTec
  • Nanjing Enhancer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drug Carcinogenicity Testing Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drug Carcinogenicity Testing Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Drug Carcinogenicity Testing Market Dynamics
  1. 2.1 Drug Carcinogenicity Testing Industry Trends
  2. 2.2 Drug Carcinogenicity Testing Industry Drivers
  3. 2.3 Drug Carcinogenicity Testing Industry Opportunities and Challenges
  4. 2.4 Drug Carcinogenicity Testing Industry Restraints
3 Drug Carcinogenicity Testing Market by Company
  1. 3.1 Global Drug Carcinogenicity Testing Company Revenue Ranking in 2025
  2. 3.2 Global Drug Carcinogenicity Testing Revenue by Company (2021-2026)
  3. 3.3 Global Drug Carcinogenicity Testing Company Ranking (2024-2026)
  4. 3.4 Global Drug Carcinogenicity Testing Company Manufacturing Base and Headquarters
  5. 3.5 Global Drug Carcinogenicity Testing Company Product Type and Application
  6. 3.6 Global Drug Carcinogenicity Testing Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Drug Carcinogenicity Testing Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Drug Carcinogenicity Testing Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Drug Carcinogenicity Testing Market by Type
  1. 4.1 Drug Carcinogenicity Testing Type Introduction
  2. 4.1.1 Transgenic Mouse Assay
  3. 4.1.2 Mouse Bioassay
  4. 4.2 Global Drug Carcinogenicity Testing Sales Value by Type
  5. 4.2.1 Global Drug Carcinogenicity Testing Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Drug Carcinogenicity Testing Sales Value by Type (2021-2032)
  7. 4.2.3 Global Drug Carcinogenicity Testing Sales Value Share by Type (2021-2032)
5 Drug Carcinogenicity Testing Market by Application
  1. 5.1 Drug Carcinogenicity Testing Application Introduction
  2. 5.1.1 Medicine
  3. 5.1.2 Pharmaceutical
  4. 5.2 Global Drug Carcinogenicity Testing Sales Value by Application
  5. 5.2.1 Global Drug Carcinogenicity Testing Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Drug Carcinogenicity Testing Sales Value by Application (2021-2032)
  7. 5.2.3 Global Drug Carcinogenicity Testing Sales Value Share by Application (2021-2032)
6 Drug Carcinogenicity Testing Regional Value Analysis
  1. 6.1 Global Drug Carcinogenicity Testing Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drug Carcinogenicity Testing Sales Value by Region (2021-2032)
  3. 6.2.1 Global Drug Carcinogenicity Testing Sales Value by Region: 2021-2026
  4. 6.2.2 Global Drug Carcinogenicity Testing Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drug Carcinogenicity Testing Sales Value (2021-2032)
  7. 6.3.2 North America Drug Carcinogenicity Testing Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Drug Carcinogenicity Testing Sales Value (2021-2032)
  10. 6.4.2 Europe Drug Carcinogenicity Testing Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Drug Carcinogenicity Testing Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Drug Carcinogenicity Testing Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Drug Carcinogenicity Testing Sales Value (2021-2032)
  16. 6.6.2 South America Drug Carcinogenicity Testing Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Drug Carcinogenicity Testing Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Drug Carcinogenicity Testing Sales Value Share by Country, 2025 VS 2032
7 Drug Carcinogenicity Testing Country-level Value Analysis
  1. 7.1 Global Drug Carcinogenicity Testing Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drug Carcinogenicity Testing Sales Value by Country (2021-2032)
  3. 7.2.1 Global Drug Carcinogenicity Testing Sales Value by Country (2021-2026)
  4. 7.2.2 Global Drug Carcinogenicity Testing Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Drug Carcinogenicity Testing Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Drug Carcinogenicity Testing Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Drug Carcinogenicity Testing Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Inotiv
  2. 8.1.1 Inotiv Company Information
  3. 8.1.2 Inotiv Business Overview
  4. 8.1.3 Inotiv Drug Carcinogenicity Testing Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Inotiv Drug Carcinogenicity Testing Product Portfolio
  6. 8.1.5 Inotiv Recent Developments
  7. 8.2 Charles River Laboratories
  8. 8.2.1 Charles River Laboratories Company Information
  9. 8.2.2 Charles River Laboratories Business Overview
  10. 8.2.3 Charles River Laboratories Drug Carcinogenicity Testing Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Charles River Laboratories Drug Carcinogenicity Testing Product Portfolio
  12. 8.2.5 Charles River Laboratories Recent Developments
  13. 8.3 Creative Biolabs
  14. 8.3.1 Creative Biolabs Company Information
  15. 8.3.2 Creative Biolabs Business Overview
  16. 8.3.3 Creative Biolabs Drug Carcinogenicity Testing Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Creative Biolabs Drug Carcinogenicity Testing Product Portfolio
  18. 8.3.5 Creative Biolabs Recent Developments
  19. 8.4 Vivotecnia
  20. 8.4.1 Vivotecnia Company Information
  21. 8.4.2 Vivotecnia Business Overview
  22. 8.4.3 Vivotecnia Drug Carcinogenicity Testing Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Vivotecnia Drug Carcinogenicity Testing Product Portfolio
  24. 8.4.5 Vivotecnia Recent Developments
  25. 8.5 Aurigene Pharmaceutical Services
  26. 8.5.1 Aurigene Pharmaceutical Services Company Information
  27. 8.5.2 Aurigene Pharmaceutical Services Business Overview
  28. 8.5.3 Aurigene Pharmaceutical Services Drug Carcinogenicity Testing Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Aurigene Pharmaceutical Services Drug Carcinogenicity Testing Product Portfolio
  30. 8.5.5 Aurigene Pharmaceutical Services Recent Developments
  31. 8.6 Lhasa Limited
  32. 8.6.1 Lhasa Limited Company Information
  33. 8.6.2 Lhasa Limited Business Overview
  34. 8.6.3 Lhasa Limited Drug Carcinogenicity Testing Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Lhasa Limited Drug Carcinogenicity Testing Product Portfolio
  36. 8.6.5 Lhasa Limited Recent Developments
  37. 8.7 Wako Pure Chemical Industries
  38. 8.7.1 Wako Pure Chemical Industries Company Information
  39. 8.7.2 Wako Pure Chemical Industries Business Overview
  40. 8.7.3 Wako Pure Chemical Industries Drug Carcinogenicity Testing Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Wako Pure Chemical Industries Drug Carcinogenicity Testing Product Portfolio
  42. 8.7.5 Wako Pure Chemical Industries Recent Developments
  43. 8.8 Ichor Life Sciences
  44. 8.8.1 Ichor Life Sciences Company Information
  45. 8.8.2 Ichor Life Sciences Business Overview
  46. 8.8.3 Ichor Life Sciences Drug Carcinogenicity Testing Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Ichor Life Sciences Drug Carcinogenicity Testing Product Portfolio
  48. 8.8.5 Ichor Life Sciences Recent Developments
  49. 8.9 Frontage Labs
  50. 8.9.1 Frontage Labs Company Information
  51. 8.9.2 Frontage Labs Business Overview
  52. 8.9.3 Frontage Labs Drug Carcinogenicity Testing Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Frontage Labs Drug Carcinogenicity Testing Product Portfolio
  54. 8.9.5 Frontage Labs Recent Developments
  55. 8.10 WuXi AppTec
  56. 8.10.1 WuXi AppTec Company Information
  57. 8.10.2 WuXi AppTec Business Overview
  58. 8.10.3 WuXi AppTec Drug Carcinogenicity Testing Revenue and Gross Margin (2021-2026)
  59. 8.10.4 WuXi AppTec Drug Carcinogenicity Testing Product Portfolio
  60. 8.10.5 WuXi AppTec Recent Developments
  61. 8.11 Nanjing Enhancer
  62. 8.11.1 Nanjing Enhancer Company Information
  63. 8.11.2 Nanjing Enhancer Business Overview
  64. 8.11.3 Nanjing Enhancer Drug Carcinogenicity Testing Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Nanjing Enhancer Drug Carcinogenicity Testing Product Portfolio
  66. 8.11.5 Nanjing Enhancer Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst